DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology (CST), a leading provider of antibodies, kits and services, was honored with the 2016 CiteAb Award for “Researchers’ Choice” and for a second year in a row with the award for “Antibody Company of the Year.” Now in its second year, the CiteAb Antibody Awards aim to celebrate the very best suppliers, reagents and individuals in the research antibody sector, recognizing the efforts that are made to progress science.
Andrew Chalmers, Ph.D., founder of CiteAb, said: "The level of competition in the awards this year was very strong, so Cell Signaling Technology has done extremely well to have won in two categories. They received some glowing nominations for the researchers' choice award. At CiteAb we're looking forward to seeing the company develop and grow, and we wish the team at Cell Signaling many congratulations for their awards."
“As a company of scientists, we are humbled and honored to have our efforts recognized by the research community with these two awards. We know customers have a choice when it comes to their antibody supplier and we aim to stand apart through our rigorous development and validation processes and full-service technical support. These awards reinforce to us that the community at large values these efforts,” said Michael J. Comb, Ph.D., Cell Signaling Technology President and CEO.
CiteAb is the largest citation-ranked antibody search engine and database. It provides an impartial way to find and compare antibodies that work.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing the world’s highest quality, innovative, research and diagnostic products to accelerate biological understanding and enable personalized medicine. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Cell Signaling Technology®, and CST™ are trademarks of Cell Signaling Technology, Inc.